Multifunctional transcription factor.
+: >90% positive, +/-: 50-90% positive, -/+: 10 - >50% positive, -(+): 1-<10% positive, -: <1% positive, ?: conflicting evidence or insufficient information.
+ Lobular breast carcinoma (100%), yolk sac tumour and choriocarcinoma (100%)
+/- Estrogen receptor or HER2 positive ductal breast carcinoma (estrogen receptor and HER2 positive ~90%.
+/- Triple negative breast carcinoma (~60%), urothelial carcinoma and squamous cell carcinoma of skin (~80%), malignant mesothelioma (~60%), chromophobic renal cell carcinoma (~50%)
-/+ Salivary gland carcinomas (~40%), pancreas adenocarcinoma (~40%?), squamous cell carcinoma of uterine cervix (~30%), larynx (~20%), and lung (~10%).
-(+) Adenocarcinomas of stomach, colon, prostate, endometrium (<10%), various sarcomas. - Adenocarcinomas apart from the above mentioned, endocrine tumours.
Identification of breast carcinoma, urothelial carcinoma and pancreas carcinoma.
Uterine cervix and tonsil are recommended as positive and negative tissue controls for GATA3. In uterine cervix a weak to moderate staining reaction in the majority of the basal and intermediate squamous epithelial cells must be seen whereas the superficial epithelial cells and stroma cells must be negative.
In the tonsil the vast majority of T helper cells (Th2) in the T-zones must show an at least moderate but distinct nuclear staining reaction. No staining of B-cells should be seen.